Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial

INTRODUCTION: Migraine is the most common neurological disorder and one of the major causes of years lived with disability. Its treatment (especially of chronic forms) is often challenging and accompanied with adverse effects. Although new therapeutic approaches have recently emerged (eg, calcitonin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Katharina, Kleine-Borgmann, Julian, Holle-Lee, Dagny, Gaul, Charly, Bingel, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230930/
https://www.ncbi.nlm.nih.gov/pubmed/34162645
http://dx.doi.org/10.1136/bmjopen-2020-045969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230930/
https://www.ncbi.nlm.nih.gov/pubmed/34162645
http://dx.doi.org/10.1136/bmjopen-2020-045969

Ejemplares similares